News

Hope in Action: ULF Board Member’s Son Receives World’s First SLC6A1 Treatment

News / December 11, 2025

We are excited to share a powerful new People Magazine feature highlighting our ULF Board Member Amber Freed and her son Maxwell, and the extraordinary journey that led to a groundbreaking milestone in rare disease history. In the article, Amber’s son Maxwell is described as having a neurodevelopmental condition known as SLC6A1, a rare genetic …

Hope in Action: ULF Board Member’s Son Receives World’s First SLC6A1 Treatment Read More »

Strength for Today, Hope for Tomorrow: Laila’s Story

News, Share Your Story / December 8, 2025

Strength for Today, Hope for Tomorrow: Laila’s Story https://ulf.org/wp-content/uploads/2025/12/Laila-2.mp4 We are Sam and Angela, and this is the story of our daughter, Laila. Our journey with leukodystrophy began when our daughter, Laila, was diagnosed with MLC1 with subcortical cysts at just 2 years old. Today, she is 14. She began walking independently, though with a …

Strength for Today, Hope for Tomorrow: Laila’s Story Read More »

A Family’s Journey with ALD – Robert & Nancy

Give 2025, News, Share Your Story / November 17, 2025

Robert & Nancy: A Family’s journey with ALD When a family faces a leukodystrophy diagnosis, the journey can feel overwhelming and isolating. That’s where the United Leukodystrophy Foundation (ULF) comes in. Since 1982, ULF has provided families with life-changing information and resources, access to expert care, and a compassionate, connected community that ensures no one …

A Family’s Journey with ALD – Robert & Nancy Read More »

New Global Guidelines Issued for Vanishing White Matter (VWM)

News / November 19, 2025

New Global Guidelines Issued for Vanishing White Matter (VWM) — A Significant Step Forward for Families and Care Teams We’re pleased to share a major advancement in the care of VWM. A new international consensus document has just been published, offering evidence- and expert-based recommendations for the diagnosis and clinical management of VWM. This is …

New Global Guidelines Issued for Vanishing White Matter (VWM) Read More »

New Global Patient Registry for MicrogliopathiesGlia

News / November 10, 2025

GliaConnect has launched a new global patient registry for individuals and families affected by microgliopathies such as ALSP, BANDDOS, and Nasu-Hakola Disease. In partnership with Sanford CoRDS, this registry helps bring together patients, families, and researchers to advance understanding and treatment of these rare disorders. The data collected will help identify symptoms, improve care management, …

New Global Patient Registry for MicrogliopathiesGlia Read More »

Positive Results Announced for Alexander Disease Clinical Trial

Clinical Trials, News / September 22, 2025

Ionis anounces positive topline results from pivotal study of zilganersen in Alexander disease The Ionis Zilganersen Team shared a message with the Alexander disease community: September 22, 2025 Dear Alexander disease community, Ionis announced today positive initial results from the pivotal clinical trial (NCT: 04849741)1 of zilganersen (ION373) in people with Alexander disease (AxD). In …

Positive Results Announced for Alexander Disease Clinical Trial Read More »

The Hidden Impact of Vanishing White Matter (VWM) on Families

News, Research / September 4, 2025

New Research Sheds Light on the Burden for Parents, Siblings, and Partners A groundbreaking international study has revealed something our community has long known: Vanishing White Matter (VWM) doesn’t just affect patients. It deeply impacts their families too. A new study, “The impact of vanishing white matter on unaffected family members,” published in the Orphanet …

The Hidden Impact of Vanishing White Matter (VWM) on Families Read More »

Minoryx’s Leriglitazone MAA for cALD Validated by EMA

News / July 25, 2025

EMA Validates Minoryx’s Marketing Application for Leriglitazone to Treat cALD Minoryx Therapeutics, a clinical-stage biotech company focused on orphan central nervous system (CNS) diseases, has announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for leriglitazone (NEZGLYAL®). This milestone marks an important regulatory step toward approval of a first-in-class oral …

Minoryx’s Leriglitazone MAA for cALD Validated by EMA Read More »

ALEXANDER DISEASE CAREGIVER Information

News / March 11, 2025

Just Worldwide is conducting a market research study on behalf of a pharmaceutical company. The study aims to gather insights from caregivers of people with Alexander Disease to better understand their experiences and opinions. The research involves a 40-minute online survey. Participants who complete the survey will receive $100 as compensation for their time. If …

ALEXANDER DISEASE CAREGIVER Information Read More »